Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ziftomenib
- Development stage
- Approved
- Lead developer
- Kura Oncology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ziftomenib is a **selective, oral, once-daily small-molecule menin inhibitor** developed by Kura Oncology and Kyowa Kirin for genetically defined acute leukemias. It disrupts the menin-KMT2A interaction and downstream leukemogenic transcriptional programs that are particularly important in **NPM1-mutated** and **KMT2A-rearranged** acute myeloid leukemia. Ziftomenib received FDA approval in November 2025 as **Komzifti** for adults with relapsed or refractory acute myeloid leukemia with a susceptible **NPM1 mutation** and no satisfactory alternative treatment options, based on the pivotal KOMET-001 study. The drug is also being studied in broader AML settings, including frontline combinations and KMT2A-rearranged disease, with Kura leading key U.S. activities and Kyowa Kirin supporting global development and ex-U.S. commercialization.
- Brand names
- Komzifti
- Other names
- KO-539KO539KO 539compound 151 [US10781218B2]
02
Targets
Menin-Lysine Methyltransferase 2A protein-protein interaction interface
Beyond the preview
Go deeper on ziftomenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ziftomenib.